Not sure which of these you qualify for?

Answer a few questions and get a ranked list of grants matched to your organization — free, no account required.

Get Your Matches →

Grants

24,059 grants found

24 grants worth up to $7.7M match your search

Enter your email to see grant names, funders, and application links

Developing an AI-Powered Speech Annotation and Transcription Enhancer Tool

open

NIDCD - National Institute on Deafness and Other Communication Disorders

PROJECT SUMMARY/ABSTRACT Language Sample Analysis (LSA) is the gold standard for Speech-Language Pathologists (SLPs) to evaluate functional communication, but manual annotation is slow and inconsistent, taking 7–8 minutes per minute of speech. This bottleneck delays interventions and exacerbates workforce strain, with 55% of SLPs reporting excessive caseloads. Existing tools such as SALT, CLAN, and Whisper offer only partial automation and lack comprehensive, multi-layer analysis. With the U.S. speech therapy market valued at $4.62 billion in 2023 and projected to grow to $8.37 billion by 2032 (CAGR 6.9%), there is strong demand for efficient, scalable, and clinically useful technologies that address SLP workflow needs. We propose SATE (Speech Annotation and Transcription Enhancer), an AI-powered platform that automates multi-layer LSA with high accuracy and usability. SATE delivers precise annotations across word- and phoneme-level transcription, C-unit segmentation, phonetic analysis (e.g., mispronunciation detection), maze identification (pauses, repetitions, filler words), morpheme and syllable analysis, and grammar evaluation. Outputs are presented in interactive reports with dynamic visualization and enable real-time editing, enabling efficient review and refinement for SLPs. The system leverages both a proprietary dataset and multiple public corpora (e.g., ENNI, L2-ARCTIC, Rescorla, UltraSuite) to ensure robustness across linguistic accents, dialects, and demographic groups. Phase I will validate technical performance on typical and disordered speech, targeting ≥0.8 sensitivity and specificity (95% CI), and assess usability and adoption through participatory studies with 20 SLPs and heuristic evaluation by 8 HCI experts. Success will be defined by robust annotation accuracy, strong usability ratings, and preliminary evidence of financial feasibility. By reducing the time, effort, and variability of LSA, SATE will expand service capacity, alleviate clinician burden, and improve access to high-quality speech and language evaluation. Completion of Phase I will provide the technical, clinical, and commercial foundation for Phase II validation, workflow integration, and SaaS-based commercialization, positioning SATE to transform LSA and strengthen speech and language service delivery.

Up to $306K

2027-06-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing an Index of Peer Support Specialist Work Settings and Activities

open

NIDA - National Institute on Drug Abuse

PROJECT ABSTRACT Substance use disorder (SUD) and overdose deaths represent a national public health crisis. Recovery is the recommended outcome for individuals with SUD, however, access to treatment and recovery supports varies greatly across the U.S., and many who could benefit from them do not receive services in part due to stigma, difficulty navigating a complex service continuum, wait times, and costs. Peer support specialists (PSS) are individuals in recovery from a SUD who are trained, certified, and employed to assist and provide guidance to patients in various states of recovery. The prima facie practical value of peers in support roles is high, as they can engage individuals outside traditional boundaries and extend the reach of care beyond clinical settings. PSS lived experience may make them more relatable than other medical or social service staff. Moreover, peer support represents a mechanism that could advance long-term recovery at lower expense relative to services delivered by other licensed clinical personnel. Regrettably, the evidence for PSS services is relatively scant in part due to methods that are ill-fitted to measure the dynamic, behavioral, and interactive process of recovery across time and within a complex service continuum. Consistently, the existing literature points to the lack of a uniform taxonomy (job titles, service roles, job-related activities, work settings) as an impediment to advancing the research on PSS provider service. In response, the Developing an Index of Peer Support Specialist Work Settings and Activities study will identify the fundamental components of PSS service delivery providing the foundation for subsequent researchers to perform rigorous effectiveness research on the public health impact of PRSS service provision. The following Aims will be accomplished building upon two preliminary studies characterizing PSS work roles and activities: 1) conduct a psychometric review of Survey 2.0 and align survey constructs within a social ecological systems framework; 2) verify PSS work roles and activities within regional recovery networks; 3) authenticate the Peer Support Specialist (PSS) Work Settings and Activities Index. A dynamic team, jointly led by investigators and consultants within the Consortium on Addiction Recovery Science (CoARS) in collaboration with state and national PSS associations and credentialing bodies, offer assurance of the successful execution of these Aims. This proposed work is innovative as it seeks to shift the standard paradigm of research design and survey construction by engaging working PSS and researchers with lived experience of SUD in the co-creation of survey instruments grounded in social ecological system theory. The proposed work is significant as it addresses a key barrier to the accurate assessment of PSS service. Results will open the door for high-quality scientific exploration into the effectiveness of PSS service provision and inform the effective deployment of PSS interventions across regional service systems.

Up to $158K

2028-02-29

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Evaluating a Digital Therapy for Comorbid Anxiety Disorders and Alcohol/Cannabis Use Disorders

open

NIDA - National Institute on Drug Abuse

Abstract Comorbid anxiety disorders and substance use disorders (SUD) are associated with poor clinical and functional outcomes. Identifying solutions for the treatment of this comorbidity is critical to improving public health. Theoretical models, clinical trials, and policy support the use of treatments that simultaneously address both problems in clinically meaningful ways, as opposed to separate treatments for each problem, which can lead to poorer clinical outcomes and barriers to care. Digital therapeutics specifically designed for those with comorbid anxiety disorders and SUD are lacking and yet have the potential to increase access to evidence-based behavioral treatment that is currently inaccessible. Although digital interventions exist separately for anxiety disorders and for SUD, none have been developed to address the unique needs of the prevalent and high-risk population of those with comorbid anxiety/SUD. This study builds upon Dr. Wolitzky-Taylor’s innovative program of work in developing and evaluating CBT protocols for this comorbidity by adapting her treatment model to a digital platform. This study aims to develop and evaluate the preliminary efficacy of a digital therapeutic for comorbid anxiety/SUD, Anxiety Management Treatment for SUD (AMT/SUD). As a first step, although the intervention is framed transdiagnostically and relevant across the anxiety and substance use disorders, the target population will be those with mild to moderate cannabis and/or alcohol use disorder, as digital therapy is an appropriate primary modality for this SUD population. First, an iterative, human-centered design process will be used to develop the mobile application-based intervention. This will include a series of focus groups to improve upon a prototype of the application, development of the application, and a small open trial (n=8) to assess for usability and to identify and address any issues prior to the randomized clinical trial (RCT). Next, a pilot RCT will be conducted with adults (N=60) with comorbid anxiety disorders and SUD (recruited from the community and several clinics who serve this population but do not provide integrated care for both problems). Participants will be randomized to either (a) “AMT/SUD”, in which they will engage with the digital therapy (which will include the option for on-demand clinical coaching on the digital content) for 12 weeks, or (b) “SUD-track”, an active control condition in which participants will be instructed to engage with Quitzilla, a publicly available substance use (and other behavior) tracking/monitoring app with motivational content, for 12 weeks. Participants will be assessed on treatment acceptability at post-treatment, and on anxiety and substance use outcomes at baseline, and 3- and 6-mo follow-ups. Following the RCT, additional patient focus groups will be conducted to inform additional refinements to the AMT/SUD mobile application-based CBT program. This digital therapeutic has the potential to make a substantial public health impact.

Up to $188K

2029-02-28

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Evaluating a Firefighter Self-Administered Neurostimulation Intervention for Traumatic Stress to Reduce Alcohol Use

open

NIAAA - National Institute on Alcohol Abuse and Alcoholism

PROJECT SUMMARY Background. Firefighters are repeatedly exposed to potentially traumatic events and many experience posttraumatic stress (PTS) symptoms as a result. Over 50% of firefighters report past-month heavy alcohol use and many use alcohol to “self-medicate” from symptoms of hyperarousal, intense negative affect, and insomnia that follow traumatic events. Transcutaneous auricular neurostimulation (tAN) of the vagus nerve has shown promise for alleviating symptoms of PTS and opioid withdrawal symptoms but its effects have yet to be tested in a sample of firefighters with alcohol use disorders (AUD) and co-occurring PTS symptoms. Aims. We will collaborate with a firefighter Community Advisory Board to develop a culturally informed, Phase II randomized clinical trial (RCT) protocol testing tAN as an intervention that may reduce PTS symptoms driving heavy alcohol use for firefighters with AUD (Aim 1; Year 1). We will then conduct a feasibility trial of the protocol (Aim 2; Year 2; N = 20) using the Sparrow device—a patient-administered, ear worn device that delivers electrical stimulation to branches of the vagus and trigeminal nerves—to evaluate the acceptability and feasibility of the protocol, and the appropriateness of the tAN intervention for firefighters with PTS/AUD. Using data from the feasibility study, we will complete an FDA pre-submission with the revised trial protocol to support a PTS/AUD indication for Sparrow Ascent, finalize the protocol with FDA feedback, and write an R01 application for a fully powered Phase II RCT (Aim 3; Year 3). Methods. The feasibility trial will recruit firefighters who engage in heavy drinking, have at least a mild AUD, and report above-average PTS symptoms. Participants will use the Sparrow device for at least 1 hour/day for 5 days/week throughout the 4-week treatment phase, but may use the device more often if they wish. Participants in the active tAN condition (n = 10) will receive therapeutic stimulation from Sparrow; active sham participants (n = 10) will feel stimulation at the trigeminal site only, but below a therapeutic level. They will complete daily measures of traumatic event exposure (number and type), PTS symptom severity, alcohol use (standard drinks) and motivations (trauma-related drinking), and audio journals capturing their experience with symptoms and the device (e.g., helpfulness). Additionally, wearable sensors will record heart rate, heart rate variability, and sleep data throughout the intervention phase. Assessments immediately following treatment (Week 4) and one month later (Week 8) will measure protocol feasibility and tAN’s clinical effects outcomes including insomnia, mental health symptoms, and quality of life. Outcomes. The primary feasibility outcome is the mean of protocol ratings on the Feasibility of Intervention Measure. Secondary feasibility outcomes include ratings of protocol acceptability (Acceptability of Intervention Measure) and Sparrow Ascent appropriateness (Intervention Appropriateness Measure). Exploratory clinical outcomes include reductions in PTS symptom severity scores and heavy drinking events.

Up to $228K

2029-04-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Evaluating a Machine-Learning Buprenorphine Care Discontinuity Prediction E-Tool (BUP-CARE)

open

NIDA - National Institute on Drug Abuse

Project Summary Over 81,000 Americans died from opioid overdose in 2023. Opioid overdose and opioid use disorder (OUD) impose significant societal and economic burdens, making sustained OUD treatment a critical public health priority. Buprenorphine, an evidence-based therapy for OUD, reduces overdose and mortality risks with >6 months of therapy. Yet, >50% of patients discontinue it within 6 months of initiation, increasing relapse and mortality risks. Primary care providers (PCP) prescribe >60% of buprenorphine prescriptions and are expected to prescribe more following elimination of the federal waiver requirement, highlighting their role in treatment retention. Although PCPs may recognize some patients at risk of discontinuation, they face time constraints, competing demands, and a lack of systematic clinical decision support (CDS) tools to integrate multi-faceted risk factors to efficiently identify patients at high risk of buprenorphine discontinuation. Accurate prediction of buprenorphine discontinuation can better inform tailored interventions, such as long-acting injectable buprenorphine and peer recovery support, to improve retention and outcomes. Prior studies using traditional regression-based methods have identified individual risk factors of buprenorphine discontinuation; however, little is known about whether these single factors accurately predict such risk. In addition, using these methods to predict buprenorphine discontinuation proves to be challenging because of their limited ability to handle complex relationships between predictors and outcomes. Machine learning offers an alternative, uncovering hidden patterns in complex data and generating precise prediction algorithms and risk stratification subgroups to guide clinical care and interventions. Our prior work has successfully applied machine learning to claims data to identify commercially insured patients at high risk of buprenorphine discontinuation. Leveraging our prior work, we propose to develop and evaluate a machine-learning buprenorphine care discontinuity prediction e-tool (BUP-CARE) for PCPs within healthcare systems to identify patients at high risk of buprenorphine care discontinuity. We have 2 specific aims. Aim 1 will use OneFlorida+ electronic health records (EHR) data from 2014 to 2025 in the PCORnet Common Data Model to develop and validate machine-learning prediction algorithms to identify patients at high risk of buprenorphine discontinuation. We will expand our previous work by incorporating advanced deep learning (e.g., recurrent neural network) for risk prediction and by including social determinants of health as predictors. Aim 2 will identify barriers and facilitators for developing a BUP-CARE CDS tool to alert front-line PCPs for patients at high risk of buprenorphine discontinuation. We will use an iterative user-centered design approach to enhance BUP-CARE’s functionality and usability. Our proposed research is highly innovative and clinically relevant in its use of a machine learning- based CDS tool to guide clinical practice and tailor evidence-based interventions, thereby optimizing resource allocation and reducing patients’ buprenorphine care discontinuity.

Up to $440K

2028-02-28

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Evaluating a Personalized Approach to Initial Fluid Resuscitation in Patients with Hospital-Onset Sepsis

open

NHLBI - National Heart Lung and Blood Institute

PROJECT SUMMARY Candidate’s Long-Term Career Goal: Dr. Elizabeth Munroe’s career goal is to become an independent physician-scientist leading novel clinical trials to improve the early management of critically ill patients. Clinical Problem to be Addressed: Intravenous fluids are a core component of sepsis management. Yet, administering both too much and too little fluid can cause harm, and the optimal fluid volume to prescribe is often unclear. Traditional clinical trials miss the critical window of initial fluid resuscitation and use one-size-fits- all approaches to fluid resuscitation. Furthermore, like most sepsis research, fluid trials have largely excluded patients who develop sepsis in the hospital (hospital-onset sepsis), an important and distinct population that experiences two-times higher mortality than patients with community-onset sepsis. Specific Aims: In this K23 proposal, Dr. Munroe aims to 1) understand the impact of initial fluid volume on outcomes in patients with hospital-onset sepsis through an electronic health record (EHR)-based cohort study, 2) develop a personalized, physiology (stroke volume) guided approach to initial fluid resuscitation for patients with hospital-onset sepsis, and 3) conduct a pilot pragmatic clinical trial comparing personalized, stroke volume guided initial fluid resuscitation vs usual care during rapid response evaluations. Candidate Background: Dr. Munroe is a clinical instructor in Pulmonary and Critical Care at the University of Michigan and current NHLBI NRSA F32 awardee. She will be promoted to Assistant Professor, not contingent on the outcome of this application. She is recognized as a rising star in the field of sepsis, with 6 first-author publications, 8 conference presentations, and 5 national invited lectures. Career Development Plan: Through this project, Dr. Munroe will build on her expertise in sepsis management and health services research to gain expertise in 1) EHR-data extraction, 2) implementation science-based intervention design and evaluation, and 3) pragmatic clinical trial design, execution, and analysis. Her 5-year training plan carefully pairs her training and research aims and is further supported by curated coursework and career development activities that will position her for successful transition to independence. Mentors: Dr. Munroe’s primary mentor, Dr. Hallie Prescott, is a sepsis expert who has mentored 5 clinician- scientists on K-series/career development awards. Dr. Munroe and Dr. Prescott have an excellent track record of success, working together since 2020. Dr. Munroe will receive complementary support from co-mentors: Dr. Michael Sjoding (EHR-based data science), Dr. Stephanie Parks Taylor (implementation science), and Dr. Robert Hyzy (clinical trials), as well a national advisory team with deep expertise in pragmatic clinical trials. Deliverables: Completing these aims will advance our understanding of fluid resuscitation in hospital-onset sepsis, generate preliminary data to compete for R-series awards for follow-up trials, and uniquely position Dr. Munroe to lead novel clinical trials of early interventions in critical care.

Up to $171K

2029-11-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Evaluating Visual, Auditory, and Tactile and Text Digital Thematic Map Viewer to Provide Blind and Low Vision Individuals Full Access to Thematic Maps for the First Time

open

NEI - National Eye Institute

Project Abstract This proposal aims to transform the accessibility of digital thematic maps for the 285 million blind and low vision (BLI) individuals worldwide. Thematic maps are essential for understanding complex data in various domains, including climate analysis, electoral processes, and emergency management. However, these maps are currently inaccessible to BLI individuals, as screen readers often fail to recognize them, and they lack customization options for low vision users. If an alternative is provided, it is a simple table lacking any geographic information. This project seeks to commercialize Audiom, an innovative, multimodal, and Large Language Model (LLM) chat-based digital map viewer. Unlike existing alternatives, Audiom is designed to be fully compliant with Web Content Accessibility Guidelines (WCAG), enabling BLI individuals to engage fully in scientific and civic domains. The project will develop Audiom from a prototype into a fully commercial platform that integrates with mainstream map tools, laying the groundwork for further research into non-visual and multimodal cartography. Audiom offers a unique visual experience for low vision users, allowing customization through speech, textures, and high contrast borders. For non-visual users, Audiom provides an auditory and tactile experience, enabling navigation through a map with arrow keys or touchscreen swipes, with pitch and speech indicating the value of features. The specific aims of this project are threefold: 1) Optimize user performance with the Audiom interface through user-centered design iterations; 2) Execute community-based comparative usability studies to evaluate Audiom's effectiveness for BLI and sighted users; and 3) Create, commercialize, and distribute a productionready Software Development Kit (SDK) for accessible digital thematic maps, facilitating easy integration with existing digital map tools. By achieving these aims, Audiom will not only make thematic maps accessible to BLI individuals, ensure compliance with the Americans with Disabilities Act (ADA) and the Rehabilitation Act for government entities, but also make mainstream the field of non-visual cartography. The commercialization of Audiom will empower BLI scientists, enhance civic participation, and improve the quality of life for BLI individuals by allowing them to use digital maps for the first time.

Up to $1.0M

2027-08-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and Piloting a Parent-Facing Tool to Improve Neonatal Clinical Trial Recruitment

open

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

PROJECT SUMMARY/ABSTRACT The neonatal intensive care unit (NICU) setting is a challenging environment for research enrollment decision- making. NICU parents are often asked to consider research enrollment at a time of high stress, to make a decision within a narrow enrollment window, and, in many cases, to do so with no previous experience either being in the NICU or participating in clinical research. Our prior work, which has examined NICU parents’ perspectives about research and developed relationship-oriented communication approaches to guide researchers during recruitment and informed consent discussions, suggests that NICU parents would be better able to engage in research discussions if they had advance preparation. This project aims to address this gap by developing and piloting a parent-facing tool to improve NICU parents’ readiness to engage with clinical researchers. Based on our prior work, we expect that such a tool can promote higher quality informed consent discussions and improve parents’ experiences, which on a population level we expect to increase overall enrollment in NICU clinical research. In this project, we will first develop a parent-facing tool, guided by the framework of Intervention Mapping, a rigorous method that will allow for tool development that is informed by relevant stakeholder values and behavioral theory. The web-based tool, accessible via a mobile device, will use multimedia and interactive features to share key topics about NICU clinical research. Second, we will pilot test the feasibility and acceptability of administering the parent-facing tool to NICU parents in 3 US NICUs (Seattle, WA; Houston, TX; Boston, MA). Primary outcomes of feasibility of integrating the tool into NICU clinical practice and acceptability of the tool to key stakeholders will be evaluated through surveys of NICU physicians and nurses, interviews of NICU research staff, surveys of NICU parents after reviewing the tool, and embedded usability metrics within the tool. Secondary outcomes to estimate impact on parents’ preparedness for decision-making and enrollment rates will be measured through additional parent survey measures and clinical trial enrollment logs. Informed by the results of this pilot study, we will refine the parent-facing tool and incorporate it alongside our previously developed researcher-facing intervention to evaluate their joint impact on parental decision-making.

Up to $253K

2028-05-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing and validating the Communicating Needs with Care Partners Scale (CONNECT): a person-centered brain injury outcome measure

open

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

PROJECT SUMMARY In this multi-site study, we will develop and validate the Communicating Needs with Care Partners (CONNECT) scale, which assess recovery of basic communication, a highly valued, but rarely measured milestone of severe brain injury recovery. Severe brain injury affects more than one million people worldwide each year. The most common cause of in-hospital deaths is withdrawal of life-sustaining treatment due to poor prognosis. There are no treatments proven to accelerate recovery from acute brain injury and no prognostic tools that can accurately predict outcome at the individual patient level. One factor contributing to these gaps is the imprecision of brain injury outcome assessment tools which rely on broad categories of global function to determine whether recovery is “favorable” or “unfavorable”. Multiple studies by our group and others indicate that the ability to communicate is a meaningful and desired outcome for persons with brain injury and their caregivers. Communication restores autonomy and provides a neuroanatomically-based target for intervention. Yet, there are no robust measures of communication that are designed for persons with brain injury. We developed a prototype of CONNECT and propose to finalize its content, assess its validity and reliability, and evaluate its Rasch measurement properties. CONNECT is administered to care partners as a structured interview that can be completed remotely. Assessment ranges from attempt to communicate at the floor to accurate expression of basic needs at the ceiling. First, we will work with clinicians, investigators, persons with brain injury, and care partners to finalize CONNECT items, establish content and face validity, and develop an administration and scoring guide. Then we will assess CONNECT’s concurrent validity, predictive validity, inter- rater reliability, test-retest reliability, and care partner variability in patients with brain injury enrolled at two acute care hospitals. We will use Rasch analyses to determine whether CONNECT is monotonic (i.e., rating scale options occur sequentially), hierarchical (i.e., items are arranged along a gradient of increasing difficulty), and unidimensional (i.e., items reflect the same underlying latent trait, recovery of communication). This study leverages an interdisciplinary team of neuroscientists, rehabilitation measurement experts, occupational therapists, and speech language pathology specialists, with expertise and experience in developing diagnostic and prognostic tools for patients with severe brain injury. CONNECT has the potential to accelerate treatment discovery, detect functional improvement and decline that would otherwise go undetected, and contribute to the development of precise prognostic models that inform decisions about withdrawing life- sustaining treatment after brain injury.

Up to $756K

2031-04-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing breath biomarkers of S. aureus cystic fibrosis lung infections through the secondary analysis of IMPACT-Breath clinical study data

open

NHLBI - National Heart Lung and Blood Institute

Staphylococcus aureus is the most common cause of lung infections in the US cystic fibrosis (CF) population, with nearly half (48.3%) of persons with CF testing positive for S. aureus in 2023. Testing for CF lung infections heavily relies upon the collection of sputum, but as CF care improves through the use of highly effective cystic fibrosis transmembrane conductance regulator therapy, the production of sputum has declined, though the risk of lung infections persists. Therefore, novel methods for diagnosing lung infections without sputum are urgently needed. Our goal is to develop highly sensitive and specific, non-invasive breath tests for the detection of S. aureus and other lung infections. The overall objective of this proposal is to develop biomarkers for S. aureus lung infections through the secondary analysis of breath volatilomics data and clinical metadata collected for the IMproving P. Aeruginosa deteCTion using Breath (IMPACT-Breath) clinical study. We hypothesize that breath biomarkers can detect S. aureus lung infections and discriminate them from other mono-infections and co-infections with > 80% accuracy. We will test this hypothesis via three Specific Aims: Aim 1: Identify biomarkers that differentiate breath samples from pwCF who are Staphylococcus aureus positive vs. negative. Using machine learning algorithms, we will build classification models that discriminate breath samples from subjects with new or chronic S. aureus infections (Sa+) vs. S. aureus negative (Sa-). Aim 2: Identify breath biomarkers that differentiate S. aureus vs. P. aeruginosa lung infections. P. aeruginosa is the second most common lung pathogen in the US CF population and in the IMPACT-Breath study cohort. Using the P. aeruginosa infection status from the IMPACT-Breath study, we will build classification models that discriminate breath samples from subjects infected with S. aureus vs. P. aeruginosa (Sa+ vs. Pa+). Aim 3: Identify breath biomarkers that differentiate S. aureus mono-infections from S. aureus-P. aeruginosa co-infections. Using IMPACT-Breath data, we will build classification models that discriminate breath samples from subjects with S. aureus mono-infections vs. S. aureus–P. aeruginosa co-infections (Sa+ vs. Sa+Pa+). The expected outcomes of this project are putative breath biomarkers for detecting S. aureus lung infections and estimates of their sensitivity and specificity, which will provide us with the necessary preliminary data to design a prospective clinical study to validate S. aureus biomarkers in the breath of pwCF.

Up to $234K

2027-04-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing cardiac organoids with deliberate heterogeneity for modeling sinus node dysfunction

open

NHLBI - National Heart Lung and Blood Institute

ABSTRACT Sinus node dysfunction (SND) is a significant heart rhythm disorder that affects both young patients with congenital heart conditions and adults due to aging or secondary complications from other heart diseases. For symptomatic patients, pacemaker implantation is often required, particularly in children, where it frequently indicates worsening heart function and poor clinical outcomes. Despite its high prevalence, the underlying causes and progression of SND remain poorly understood. A major challenge in advancing treatments is the lack of a reliable human model that effectively replicates the sinoatrial node and its dysfunction. This project aims to address this gap by utilizing human cardiac pacemaker organoids derived from iPSCs to model SND. We hypothesize that integrating nonmyocytes into these organoids plays a crucial role in accurately mimicking the sinoatrial node and the progression of SND. By applying constant or cyclic mechanical strain, we will simulate the disease environment to better understand its mechanisms. These organoids will mirror the cellular diversity of the native sinoatrial node, offering a rigorous platform to explore the etiology of SND. The ultimate goal is to identify key molecular targets that could lead to novel therapies, reducing the need for permanent pacemaker implants and improving patient outcomes.

Up to $426K

2028-03-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Case Studies from Pre/Post Natural disaster monitoring of natural features

open

Engineer Research and Development Center

This work represents an opportunity to develop case studies highlighting the performance/impact to natural features or natural and nature based features (NNBF) during recent natural disaster events such as hurricanes, and flooding. Many university researchers have gathered recent pre/post storm data using various metrics. While there are often mechanisms to collect data, opportunities to analyze the collected data and develop case studies are not always feasible. This requirement is to develop a subset of sampling events into a case study in collaboration with USACE. This is an opportunity to identify and use existing data from past storm seasons to develop case studies demonstrating the performance of natural features. Ultimately, case study results would also be used to relate natural performance to anticipated performance of NNBF features. Case studies could be focused on natural features such as dunes, marshes, reefs, etc. or NNBFs. Previously collected data used to develop case studies might include (but is not limited to) a combination of wave attenuation and water movement data, sediment transport data, elevation data, and vegetation or other ecological data. The findings of this cooperative agreement will be made publicly available through the release of public reports or peer-reviewed journal articles as well as a public seminar describing results. The Government will be involved with the research by providing technical guidance on the research, assisting with the experimental design, and collaborating on the journal articles. The Government is not expecting the periods of performances to overlap. Identified project tasks are: 1. Describe previously collected data and justification for how it can be used as a case study for monitoring natural or NNBF features pre/post natural disaster.2. Work collaboratively with ERDC to analyze data and develop case study/.3. Work collaboratively with ERDC publish case study via ERDC or peer reviewed publications. Requirements: Successful applicants should have expert knowledge of 1) NNBF and Natural features, 2) available pre and post natural disaster (e.g., hurricane, flood event, etc.) monitoring data in hand associated with a natural feature or NNBF, and 3) knowledge of planned statistical approaches for analysis of those datasets. Areas of expertise required to perform this study include:1) Knowledge and experience monitoring extreme events.2) Statistical analysis. Applicants will be required to submit quarterly status reports and a final report within 4 months of completion of the study. ERDC and the candidates will develop a draft of the journal article or articles for internal peer review during cooperative agreement s period of performance.

Up to $24K

rolling

sciencetechnology

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Civilizational Bonds, Democratic Resilience, and Rule of Law in Europe

open

Bureau of Democracy Human Rights and Labor

Developing Civilizational Bonds, Democratic Resilience, and Rule of Law in Europe

2026-08-12

general

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Cognitive Control and Metacognition to Reduce the Functional Impact of Restricted and Repetitive Behaviors in Autism

open

NIMH - National Institute of Mental Health

PROJECT SUMMARY ABSTRACT Effective interventions to reduce the functional impact of core features of autism spectrum disorder (ASD) in school-aged children are critically needed. This R61/R33 application proposes to test whether in-person computer training delivered individually by a coach engages an electroencephalographic (EEG) biomarker of cognitive control (N2 event-related potential [ERP] amplitude) and whether changes in the target neural response mediate the reduction of restricted and repetitive behaviors and interests. An extensive clinical and cognitive neuroscience literature documents reduced cognitive control among autistic children compared to neurotypical children and a relation between cognitive control and repetitive features of autism––providing a solid rationale for our training program. Based on this work, we predict that developing more effective cognitive control, metacognition, and working memory will enhance neural responses to conflicting information (i.e., a neural marker of effective cognitive control) and changes will correspond with decreases in restricted and repetitive behaviors and interests. The R61 study will randomly assign 95 autistic children (ages 8-11yrs) to a novel computer-based Cognitive Control Training combined with Metacognition Coaching or to a waitlist control group. Before and after intervention, EEG will be used to examine engagement of the target neural responses. We expect the group assigned to Cognitive Control Training + Metacognition Coaching to exhibit significantly larger changes in N2 ERP amplitude in incongruent relative to congruent trials than the waitlist group. If this hypothesis is supported, the R33 will be implemented and 140 autistic children (8-11yrs) will be randomly assigned to either: 1) Cognitive Control Training + Metacognition Coaching; or 2) MentalUP Educational Games, an active control condition that provides computer-based cognitive training. Both Cognitive Control Training + Metacognition Coaching and MentalUP will be delivered individually during 15 in-person sessions. Before and after intervention, we will collect neural responses and behavioral measures of cognitive control and working memory. We expect target engagement (greater differentiation of N2 amplitude) to be associated with reduced restricted and repetitive behaviors and interests. This study is innovative in several ways and has the potential for large clinical and scientific impact. It is the first study to examine a cost-effective computer-based cognitive control intervention for ASD that provides in-person metacognition coaching. This could increase functioning for autistic children at a time when intensive intervention delivery is waning. The study will use biomarkers and validated behavioral measures of cognitive control and metacognition in the context of an ASD clinical trial. Finally, the study will provide critical information about the relation between cognitive control and clinically relevant ASD outcomes, thereby providing insight into the mechanisms underlying behavioral challenges for autistic children. Promising results from this study would provide the basis for a larger clinical trial to investigate the efficacy of cognitive control training and mediators and moderators of its effects.

Up to $991K

2028-02-29

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing computational, experimental and ecological approaches to study integrated phages and their hosts

open

NIDCR - National Institute of Dental and Craniofacial Research

ABSTRACT Bacteriophages are integral components of the human microbiome, shaping microbial diversity and influencing host health, yet our understanding of phage-host dynamics remains limited, particularly for integrated phages. Recent discoveries reveal that lysogenic phages dominate the human gut microbiome over lytic phages, but current methods using short-read sequencing fail to capture phage integration sites and host attribution. This project will elucidate integrated phage-host dynamics in the human microbiome using innovative long-read sequencing approaches. The central hypothesis of this proposal is that integrated phages play critical roles in microbial community dynamics that can be detected, experimentally tested, and modeled to advance our understanding of microbiome function. Our preliminary data demonstrates that long-read sequencing dramatically improves phage genome assembly, host attribution, and integration site identification. Specifically, we have shown that geNomad most accurately detects phage boundaries when compared to ‘gold standard’ structural variation evidence of phage boundaries from Sniffles (DNA structural variant detector). We have also successfully propagated non-plaque-forming phages using stool-based cultures and discovered that p- crAssphage (Carjivirus communis) adopts a phage-plasmid lifestyle, challenging traditional models. Additionally, we have developed a quantitative modeling framework that revealed surprisingly low rates of phage induction in the microbiome. Building upon these findings, we will: (Aim 1) develop a computational framework to identify integrated prophages, their hosts, and integration sites from long-read metagenomic data, including a nextflow pipeline for assembly and annotation; (Aim 2) establish a stool-based culturomics platform to isolate non-plaque- forming phages and identify their bacterial hosts using meta-Hi-C sequencing and qPCR-based growth dynamics analysis; and (Aim 3) create computational models for viral-host population dynamics to test longstanding hypotheses about virus-host interactions in the human gut, extending our modeling to account for within-host spatial structure. Our multidisciplinary team brings together expertise in microbiome science, genomics and clinical applications (Bhatt), quantitative modeling and microbial biophysics (Huang), and evolutionary dynamics and microbial ecology (Good). We have collaborated successfully for several years and are supported by robust computational resources and experimental facilities. This project offers technological innovations through novel long-read sequencing pipelines and conceptual advances in understanding lysogenic phage ecology and lifestyle diversity. Successful completion will yield a suite of computational and experimental methods to identify integrated phages, their hosts, and viral-host interactions within the human microbiome, significantly enhancing our understanding of how phages impact human health and potentially informing future phage-based therapeutic strategies for microbiome modulation.

Up to $539K

2030-01-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Cross Protective Vaccine to Control Leptospira Infection

open

NIAID - National Institute of Allergy and Infectious Diseases

Developing a cross-protective vaccine to control Leptospira infection Project Summary Leptospirosis is a leading zoonotic cause of human morbidity and mortality, occurring in diverse epidemiologic settings, with estimates of 1.03 million cases and 58,000 deaths per year. It is one of the underrecognized and neglected diseases of humans and animals with similar clinical manifestations. The presence of numerous Leptospira species/serovars, infecting a broad range of animal reservoirs and the resulting environmental contamination, makes control and prevention in humans and animals a cumbersome task. The bacterin-based vaccines available for animals do not offer complete protection or prevent renal colonization and urinary shedding. Due to these limitations and adverse effects, vaccination of humans is not practiced. A broader cross-protective vaccine is urgently needed to prevent Leptospira infection in humans and animals. The availability of a large number of genome sequences and advanced bioinformatics tools has allowed us to use reverse and structural vaccinology approaches to identify a repertoire of conserved antigenic epitopes from Leptospira. Probing these epitopes using a high- throughput microarray and serum from naturally infected animals resulted in identifying proteins that are exposed to the host immune system. In the proposed research, we will confirm their surface exposure and evaluate their protective efficacy in hamsters and mice. Our proposed strategy will overcome the traditional linear, time-consuming, and cost-prohibitive process of antigen discovery for vaccine design. We expect that the vaccination with a cocktail of selected candidates will induce a focused protective response toward relevent immunogenic protein regions. Our long-term goal is to develop a safe and cross-protective vaccine that provides long- lasting immunity against Leptospira infection irrespective of infecting Leptospira serovar and affected host species. Leptospirosis is a globally significant human and animal health problem and a perfect paradigm for an infectious disease of “one health” importance. Development of a cross-protective multispecies vaccine is highly desirable to control this disease, and such a product will have public health, economic, and social impact.

Up to $200K

2028-05-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Dissemination Strategies for Healthcare Providers to Advance the Reach of T1D Psychosocial Care

open

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

PROJECT SUMMARY Youth with type 1 diabetes (T1D) experience worse T1D health outcomes (higher glycemic levels, greater psychological distress) compared to adults. Evidence-based pediatric T1D psychosocial care has the potential to improve diabetes distress, high glycemic levels, and family conflict. However, few families are aware of or receive this needed care. This gap is due to limited integration of research into practice (implementation) and insufficient awareness of evidence-based psychosocial care by T1D providers, who are the trusted, preferred source of T1D healthcare information and referrals among families (dissemination). To increase the reach of this care requires both implementation strategies to ensure what is delivered in standard care is evidence-based (focus of the PIs K23DK125666), as well as dissemination strategies to increase T1D provider knowledge and utilization of this care. Dissemination efforts must center viewpoints of T1D providers to effectively tailor strategies to this target audience. The proposed study is the first to develop provider-focused dissemination strategies for evidence-based T1D psychosocial care. Guided by Designing for Dissemination (D4D), the current community-engaged study will be conducted with the PIs existing T1D Provider Partners (REACH Pilot; P20GM144270) who will guide refinement and execution of the proposed research plan from study design through dissemination. Content experts on dissemination science (Becker), mixed methods (Deatrick) and pediatric behavioral intervention in medical setting (Kazak), as well as Nemours and Breakthrough T1D Social Media Specialists will support the execution of this research. Leveraging her benchmarking study on psychosocial staffing and care in pediatric diabetes clinics, Dr. Price will use survey methodologies to gather perspectives from T1D providers (endocrinologists, advanced practice providers) nationally on preferences related to (1) What should be disseminated, (2) By whom, and (3) Where, as well as identify (4) Barriers and (5) Facilitators of accessing and using research findings (Aim 1). Individual interviews with T1D providers will be used to refine quantitative data from Aim 1 and to select and tailor dissemination tools (Aim 2). After viewing newly created dissemination tools and content, T1D providers will complete surveys on the clarity, reach, influence, and trustworthiness of these tools and strategies (Aim 3). This foundational study will result in provider- centered, ready-to-test dissemination strategies, which will bolster an R01 application to conduct a multi-site randomized trial testing dissemination strategy effectiveness on increasing T1D providers’ knowledge and utilization of evidence-based T1D psychosocial care. This research complements Dr. Price’s ongoing research on implementation science (K23 from NIDDK). With her community partnerships and complementary implementation data, the proposed dissemination project will advance her goals to become an independent investigator and improve T1D healthcare and outcomes among youth with T1D.

Up to $114K

2028-04-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Diverse Physician-Investigator Leaders for the Future of Child Health

open

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

ABSTRACT Early stage pediatric faculty members, even those who have potential for success as academic investigators based upon substantial experience in basic research, will require further intensive training and mentoring in basic research to successfully embark upon an independent research career. Our proposed Child Health Research Career Development Award (CHRCDA) Program entitled “Developing Diverse Physician-Investigator Leaders for the Future of Child Health” will provide a cutting-edge research opportunities, combined with a carefully constructed mentoring and career development pathway, to enable our Scholars to emerge as leaders among the ranks of pediatric academic investigators. The basic biomedical research training community at the University of California San Diego (UCSD) has a long-established reputation of excellence, and UCSD Pediatrics now ranks in the top five in NIH research funding of all Pediatric Departments in the country. Notably, the last 5-10 years have witnessed an impressive academic expansion within of the UCSD Department of Pediatrics and the research it conducts, coupled with the formalization of its partnership with Rady Children's Hospital San Diego, the largest Children's Hospital in California. The key objectives of our CHRCDA are as follows: (1) To increase the number Pediatrician-Scientists engaged in basic research as applied to children's health; (2) to attract outstanding young pediatricians to UCSD and to facilitate their career development under the guidance of world class, established investigator-faculty mentors; and (3) to cultivate the early careers of women and minority investigators in children's health. With close input from the program pioneers in our Department, CHRCDA Scholars will participate fully in the program of UCSD National Center for Leadership in Academic Medicine (NCLAM), a longstanding and highly successful junior faculty mentoring program in UC Health Sciences that provides workshops and longitudinal mentoring in all facets required for successful advancement in academic medicine, and diversity enrichment modules including the Border Health and Doc-for-A-Day programs. All CHRCDA program faculty mentors are highly regarded scientific investigators, each leading a vibrant and cutting-edge basic or basic/translational research program of strong relevance to pediatric medicine. Research training opportunities for CHRCDA Scholars are organized into six research themes of five members each, which an integral role in the program structure, curriculum and mentorship approach: (1) Genomics, Big Data & Systems Biology; (2) Infection, Immunity & Inflammation; (3) Organ Physiology & Metabolism; (4) Neuroscience & Brain Development; (5) Human Microbiome & Child Health; and (6) Developmental & Stem Cell Biology. A guiding philosophy of this CHRCDA will be to support the greatest possible number of young physician-scientists within this Program, and an additional year of Department-funded support has been added to three years of K12 support to create a vibrant program with one new Scholar per year and four fellows total in the steady state.

Up to $299K

2027-03-31

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

DEVELOPING EDUCATIONAL AND COMMUNITY PROGRAMS AT THE SPEAKER?S HOUSE [HISTORIC TRAPPE WILL LAUNCH A NEW SLATE OF PUBLIC ...

open

National Endowment for the Humanities

DEVELOPING EDUCATIONAL AND COMMUNITY PROGRAMS AT THE SPEAKER?S HOUSE [HISTORIC TRAPPE WILL LAUNCH A NEW SLATE OF PUBLIC HUMANITIES PROGRAMMING AT THE SPEAKER?S HOUSE, THE RESTORED HOME OF FREDERICK MUHLENBERG, FIRST SPEAKER OF THE U.S. HOUSE OF REPRESENTATIVES. TIMED TO COINCIDE WITH THE 250TH ANNIVERSARY OF AMERICAN INDEPENDENCE AND THE GRAND OPENING OF THE HOUSE IN APRIL 2026, THIS PROJECT WILL ENGAGE PUBLIC AUDIENCES WITH THE POLITICAL, RELIGIOUS, AND DOMESTIC LIFE OF THE EARLY AMERICAN REPUBLIC. EDUCATIONAL PROGRAMS INCLUDE ARCHAEOLOGY WORKSHOPS FOR CHILDREN AND FAMILIES; IMMERSIVE FOODWAYS DEMONSTRATIONS IN THE RESTORED KITCHEN; A LECTURE SERIES LED BY NATIONALLY RECOGNIZED SCHOLARS; AND CURRICULUM-ALIGNED FIELD TRIPS THAT TEACH CIVIC HISTORY THROUGH SITE-BASED INTERPRETATION.]

Up to $25K

2026-07-31

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Experts in Computation, 'Omics and Data Exploration (DECODE) Training Program

open

NIGMS - National Institute of General Medical Sciences

Abstract Biomedical research is increasingly shaped by high-throughput and multi-omic approaches that generate massive, complex datasets. However, most entering PhD students lack foundational skills in computational biology, bioinformatics, and data science, creating a widening gap between research needs and workforce readiness. The DECODE training program at the University of Nebraska Medical Center (UNMC) directly addresses this challenge by embedding rigorous computational training from the very start of graduate education. DECODE is unique among T32 programs in supporting six predoctoral trainees during their first two years of doctoral study, ensuring that computational fluency becomes a core foundation of their graduate careers. Participants are drawn from seven doctoral tracks within UNMC’s Interdisciplinary Graduate Program in Biomedical Sciences and mentored by over 53 faculty across 17 departments. The training plan integrates statistics, programming, bioinformatics, and systems biology, paired with team-based projects on real-world datasets from public repositories (e.g., GEO, TCGA, ENCODE). This training progresses into advanced applications in machine learning and AI, combined with leadership opportunities in teaching, mentoring, and hosting bootcamps. Rigor and reproducibility, data stewardship, responsible conduct of research, project management, team science, scientific writing, and communication are skills focused on and embedded throughout the activities. After year 2, trainees will have tangible outcomes direct from the program, including peer-reviewed cohort manuscripts, open-source pipelines, and software tools that serve both their dissertation research and the broader community. Metrics for program success include interdisciplinary publications, external fellowships, presentations, and placement outcomes compared to the broader student pool. DECODE is a training program that targets trainees at a critical juncture, before they have decided on a specialization. The result is a cohort of team-oriented scientists prepared to advance biomedical discovery through computational biology, bioinformatics, and biomedical data science, directly aligning with the NIGMS mission to build a versatile and data-driven biomedical research workforce.

Up to $318K

2031-06-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Global Scientists and Engineers (International Research Experiences for Students (IRES) and Doctoral Dissertation Enhancement Projects (DDEP))

open

U.S. National Science Foundation

The United States needs to educate a globally-engaged science and engineering workforce capable of performing in an international research environment in order to remain at the forefront of world science and technology. To support this aim, the Developing Global Scientists and Engineers program provides highest quality international research experiences for U.S. students. Whereas the International Research Experiences for Students (IRES) component of the program supports groups of U.S. undergraduate or graduate students conducting research abroad in collaboration with foreign investigators, the Doctoral Dissertation Enhancement Projects (DDEP) component supports the dissertation research abroad of one doctoral student in collaboration with a foreign investigator.In addition to the activities described in this solicitation, the Office of International Science and Engineering (OISE) supports other targeted international research and education experiences for early-career scientists and engineers via the Research Experience for Undergraduates program, the East Asia and Pacific Summer Institutes for U.S. Graduate Students, the Pan-American Advanced Studies Institutes (for advanced graduate students and post-doctoral fellows), and the International Research Fellowship Program (for post-doctoral fellows or new faculty). More information is provided below in Section IX. Other Programs of Interest.

$1K – $150K

rolling

sciencetechnology

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing GLP-1 Producing Genetically Engineered Probiotics for Treatment of Metabolic Diseases

open

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

PROJECT SUMMARY / ABSTRACT The increasing prevalence of metabolic diseases such as type 2 diabetes mellitus (T2DM), obesity, and associated cardiovascular risks represents a major global health challenge. The glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted in response to food intake and neuroendocrine stimulation. As an incretin hormone, GLP-1 plays a crucial role in glucose homeostasis, insulin secretion, and appetite regulation. The synthetic GLP-1 receptor agonists (GLP-1RAs) which mimic native GLP-1's pharmacological functions with extended half-lives and increased biological activity have emerged as a leading treatment for type 2 diabetes and obesity. While GLP-1RAs show promising results in various therapeutic areas beyond diabetes and obesity, significant challenges remain, which include poor patient compliance and high discontinuation rates, due to requirement of frequent injections, side effects, accessibility issue due to global shortage, and high-cost barriers. The goal of this project is to develop engineered probiotics capable of producing and continuously delivering GLP-1 both locally in the gastrointestinal (GI) tract and systemically, to overcome these challenges of GLP-1RAs-based therapies. Moreover, increasing evidence indicates that the gut microbiome plays a crucial role in the pathogenesis of metabolic diseases through multiple interconnected mechanisms and probiotics have been shown beneficial in managing these conditions; thus, engineered probiotics not only deliver GLP-1 but also could potentially modulate gut microbiota, improving intestinal health and immune function. We have developed an innovative, probiotics-based platform technology for the oral delivery of therapeutic proteins that targets several challenging chronic diseases. Our recent published results provide proof-of-concept for the feasibility of using Lactobacillus as a live vector to deliver peptides and proteins, demonstrating enhanced tissue bioavailability and efficacy. In this application, we plan to construct and characterize the engineered Lactobacillus probiotics to produce and secrete biologically active GLP-1 in the GI tract and systemically (Aim 1) and evaluate the efficacy of GLP-1 producing bacteria in the animal model of T2DM (Aim 2). The successful development of engineered bacteria for GLP-1 delivery could revolutionize diabetes treatment and have far-reaching implications in medicine. This approach could significantly improve patient adherence and quality of life by replacing frequent injections with oral administration, while providing sustained GLP-1 production for better glycemic control. It may reduce side effects and treatment costs, enabling more accessible and personalized therapies. Completion of these studies will position us to initiate Phase II studies including pharmacokinetics, biodistribution, toxicology, formulation and scaled-up GMP production of engineered probiotics producing GLP-1 for clinical application.

Up to $356K

2027-07-14

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing Improved Reporter Mouse Models for In Vivo Gene Editing

open

OD - NIH Office of the Director

PROJECT SUMMARY CRISPR-Cas9 technologies have revolutionized genetic engineering and have led to a renaissance in genetic therapy research. The initial CRISPR discovery was that of an RNA-guided endonuclease capable of creating double-strand DNA breaks which can be precisely corrected using DNA donor-mediated homology- directed repair (HDR). While an advance, this approach is complicated by low efficiency and non-therapeutic side products arising from non-homologous end joining (NHEJ). Among the most promising of various newer approaches are A- and C-base editing, which allow for precise genome modification of adenine and cytosine residues, respectively, without the generation (and drawbacks) of double-strand DNA breaks. Testing the safety and efficacy of such approaches relies on preclinical studies often performed using mouse models. To this point, mouse gene editing reporter strains serve many roles in characterizing gene editors. For example, gene editing reporter strains can be used to track the timing and location of gene editing, assess gene editing efficiency, optimize gene editor delivery, discriminate between repair mechanisms, and lay the groundwork for clinical studies through preclinical testing of emerging therapeutics. During Phase 1 of the Somatic Cell Genome Editing Consortium, The Jackson Laboratory established a Gene Editing and Testing Center to design, engineer, and deploy new reporter models. We created three new mouse gene editing reporter strains that can effectively indicate HDR, NHEJ, and A-base editing activity at single- cell resolution through the activation of a fluorescent marker. These models are now available for public distribution and are well-utilized by the therapeutic gene editing community. Despite these successes, gaps remain in the mouse gene editing and characterization toolbox limiting the number of editing outcomes that can be reliably measured, in vivo. This proposal aims to address these needs by constructing and characterizing two mouse gene editing reporter strains. The first strain will enable detection of C-base editor activity, an important editing technology with growing therapeutic interest thanks to the development of C-base editor variants with high specificity. The second strain is a multifunctional reporter that addresses the specific need for a reporter that can faithfully detect most NHEJ events, but that also reports, HDR, A-base editing, and Cre-directed recombination. In all, this multifunctional reporter assesses a number of important activities for evaluating new gene editing platforms. Each of these reporters will be functionally characterized across three levels of biological complexity, qualifying them for further use in preclinical testing.

Up to $487K

2028-06-30

health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Developing managed aquifer recharge techniques (MAR) in a rural context

open

European Commission - HORIZON

Developing managed aquifer recharge techniques (MAR) in a rural context. Call: Call 01 - single stage (2026). Programme: HORIZON. Keywords: Business analysis, Business governance, Business models, Catchment scale planning, Environmental engineering and geotechnics, Environmental impact assessment, Human impacts and other stressors, Hydrology (Water science), Natural resources and environmental economics, Nature-based solutions, Water management, Water recycling and re-use, Water technology. Open call from the EU Funding & Tenders Portal.

$50K

2026-09-17

environmenttechnologyBusiness Development+1

Free to search & build · $99 one-time to unlock the application pack · No subscription